Flexion Therapeutics Inc. (NASDAQ:FLXN) shares were down 4.2% on Tuesday . The company traded as low as $15.22 and last traded at $15.23, with a volume of 71,077 shares. The stock had previously closed at $15.90.

A number of research analysts have weighed in on FLXN shares. Janney Montgomery Scott reissued a “buy” rating and issued a $30.00 target price on shares of Flexion Therapeutics in a research note on Friday, May 27th. Needham & Company LLC reissued a “buy” rating and issued a $34.00 target price (up from $28.00) on shares of Flexion Therapeutics in a research note on Friday, May 27th. Cantor Fitzgerald reissued a “buy” rating on shares of Flexion Therapeutics in a research note on Thursday, May 26th. Wells Fargo & Co. reissued a “buy” rating on shares of Flexion Therapeutics in a research note on Thursday, June 30th. Finally, Royal Bank Of Canada reissued a “buy” rating on shares of Flexion Therapeutics in a research note on Thursday, June 30th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $32.56.

The stock has a 50 day moving average price of $15.10 and a 200 day moving average price of $12.63. The stock’s market capitalization is $330.88 million.

Flexion Therapeutics (NASDAQ:FLXN) last issued its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.17. Analysts forecast that Flexion Therapeutics Inc. will post ($2.84) earnings per share for the current fiscal year.

In related news, Director Samuel D. Colella bought 25,504 shares of the stock in a transaction on Tuesday, June 21st. The shares were bought at an average cost of $13.71 per share, for a total transaction of $349,659.84. Following the completion of the transaction, the director now owns 3,435 shares of the company’s stock, valued at approximately $47,093.85. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Samuel D. Colella bought 6,778 shares of the stock in a transaction on Monday, June 20th. The shares were bought at an average price of $13.84 per share, for a total transaction of $93,807.52. Following the completion of the transaction, the director now directly owns 3,435 shares of the company’s stock, valued at approximately $47,540.40. The disclosure for this purchase can be found here.

A number of hedge funds and institutional investors recently modified their holdings of the company. Jennison Associates raised its position in shares of Flexion Therapeutics by 35.1% in the third quarter. Jennison Associates now owns 2,831,268 shares of the specialty pharmaceutical company’s stock valued at $42,073,000 after buying an additional 736,261 shares during the last quarter. Schroder Investment Management Group increased its stake in shares of Flexion Therapeutics by 21.0% in the fourth quarter. Schroder Investment Management Group now owns 470,200 shares of the specialty pharmaceutical company’s stock valued at $9,061,000 after buying an additional 81,500 shares during the period. Wells Fargo & Company MN increased its stake in shares of Flexion Therapeutics by 16.2% in the fourth quarter. Wells Fargo & Company MN now owns 430,545 shares of the specialty pharmaceutical company’s stock valued at $8,296,000 after buying an additional 59,866 shares during the period. Finally, Jennison Associates LLC increased its stake in shares of Flexion Therapeutics by 2.7% in the fourth quarter. Jennison Associates LLC now owns 2,907,755 shares of the specialty pharmaceutical company’s stock valued at $56,032,000 after buying an additional 76,487 shares during the period.

Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.